Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0530 in Hormone Refractory Prostate Cancer
NCT00513071Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2007
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of saracatinib in prostate cancer (PCa), sponsored by National Cancer Institute. Primary endpoint: Prostate-Specific Antigen Response Rate. Started Aug 2007; status: completed.
02
Drugs
saracatinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00513071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00513071.